Why Early HTA Can Save Startups Time, Money, and Failed Market Entry

For many health technology startups, the early stages of product development are focused almost entirely on innovation. Teams work to refine the technology, secure investment, develop prototypes, and prepare for regulatory approval. However, one critical area is often overlooked until much later: Health Technology Assessment (HTA).
While HTA is sometimes seen as something that only matters after a product is finished, the reality is very different. Early HTA can help startups make better decisions from the beginning, avoid expensive mistakes, and increase the chances of successful market entry.
What Is Early HTA?
Health Technology Assessment is a structured process used to evaluate the clinical, economic, organisational, and social value of a health technology. It helps decision-makers understand whether a product provides enough benefit compared to existing alternatives.
Early HTA applies these principles before a product reaches the market. Instead of waiting until the final stages of development, startups can use HTA thinking to guide product design, evidence generation, pricing, reimbursement planning, and market strategy.
For startups with limited resources, this can be especially valuable.
Why Startups Often Struggle Without Early HTA
Many startups focus heavily on building a technically impressive product. However, technical innovation alone is rarely enough to secure reimbursement, convince payers, or achieve widespread adoption.
A product may be clinically promising but still fail because:
• It targets the wrong patient population
• It does not solve a high-priority healthcare problem
• It lacks the evidence needed for reimbursement
• It is more expensive than existing alternatives without demonstrating enough additional value
• The market is too small or difficult to access
• The product pathway does not match payer expectations
These issues often become visible only after significant time and money have already been invested.
Early HTA Helps Identify the Right Market
One of the biggest benefits of early HTA is that it helps startups identify where their technology is most likely to succeed.
A product may have multiple possible indications, patient groups, or use cases. Early HTA can help determine:
• Which indication has the highest unmet need
• Which patient population is most likely to benefit
• Where there is the strongest economic value proposition
• Which countries or healthcare systems may be more open to adoption
• Which comparators should be used in future studies
This can prevent startups from investing heavily in a market that is difficult to access or commercially unattractive.
It Supports Better Evidence Generation
Many startups only realise late in development that they are missing important evidence.
For example, they may have strong technical performance data but limited clinical outcomes data. Or they may demonstrate that a product works, but fail to show that it improves patient outcomes, reduces costs, or creates efficiencies for healthcare providers.
Early HTA helps startups plan the right evidence from the beginning. This may include:
• Clinical endpoints that matter to payers and providers
• Appropriate comparators
• Patient-reported outcomes
• Resource use and cost data
• Real-world evidence plans
• Early economic models
Generating the right evidence early can save both time and money later, especially when preparing for reimbursement submissions or investor discussions.
Early Economic Modelling Can Prevent Costly Mistakes
Economic modelling is often viewed as something that happens after a product is launched. In reality, early economic models can provide valuable insights long before market entry.
A simple early model can help answer questions such as:
• Is the product likely to be cost-effective?
• What price range may be acceptable?
• Which factors have the greatest impact on value?
• What level of clinical improvement is needed to justify adoption?
• Which market segment offers the best return on investment?
This information can guide both product development and business strategy.
For example, a startup may discover that its product only becomes economically attractive if it targets a high-risk patient group rather than the general population. Identifying this early can prevent years of development in the wrong direction.
Early HTA Improves Investor Discussions
Investors increasingly want to know not only whether a product works, but whether it can achieve reimbursement and commercial success.
Startups that can explain:
• The size of the target market
• The expected reimbursement pathway
• The likely economic value of the technology
• The evidence plan
• The barriers to adoption
are often seen as lower-risk investments.
Early HTA can therefore strengthen funding applications, investor pitches, and strategic partnerships.
It Reduces the Risk of Failed Market Entry
Failed market entry is expensive.
A company may spend years developing a product, only to discover that payers do not see enough value, hospitals are unwilling to adopt it, or reimbursement systems do not support its use.
Early HTA reduces this risk by identifying problems before they become too costly to fix.
Instead of asking, “How do we sell this product?” at the end of development, startups can ask much earlier:
• Who truly needs this technology?
• What evidence will decision-makers expect?
• How will this compare with existing options?
• Will the value justify the cost?
• Is there a realistic path to reimbursement?
These questions are often the difference between successful market access and failed commercialisation.
Final Thoughts
For startups, early HTA is not an unnecessary extra step. It is a strategic tool that can improve decision-making throughout product development.
By identifying the right market, planning the right evidence, understanding economic value, and preparing for reimbursement early, startups can reduce uncertainty and avoid expensive mistakes.
In an increasingly competitive healthcare environment, the companies that succeed are often not only the ones with the best technology, but the ones that can clearly demonstrate why that technology matters.